Condition: Coronary Artery Disease · Diabetes Mellitus, Type 2 · Dyslipidemias · Sponsor: Ruijin Hospital
Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.
This description comes directly from the study's public registry record.
Xiaoqun Wang, M.D., Ph.D. · +86 21 13651839760 · xiaoqun_wang@hotmail.com
Shuo Feng, M.D. · +86 21 15921388296 · fengshuorv@hotmail.com
Always discuss trial participation with your own doctor first.
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05117424